Reed C C, Wolf W A, Cotton C C, Dellon E S
Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, Center for Gastrointestinal Biology and Disease, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Aliment Pharmacol Ther. 2017 Jun;45(11):1443-1448. doi: 10.1111/apt.14061. Epub 2017 Mar 31.
While symptom scores have been developed to evaluate dysphagia in eosinophilic oesophagitis (EoE), their complexity may limit clinical use.
To evaluate a visual analogue scale (VAS) and a 10-point Likert scale (LS) for assessment of dysphagia severity before and after EoE treatment.
We conducted a prospective cohort study enrolling consecutive adults undergoing out-patient endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. At diagnosis and after 8 weeks of treatment, symptoms were measured using the VAS, LS and the Mayo Dysphagia Questionnaire (MDQ). The percentage change in scores before and after treatment were compared overall, in treatment responders (<15 eos/hpf) and non-responders, and in patients without baseline dilation.
In 51 EoE cases, the median VAS decreased from 3.6 at baseline to 1.4 post-treatment (71% decrease), the LS decreased from 6 to 2 (67%) and the MDQ decreased from 20 to 10 (49%). The VAS correlated with both the LS (R = 0.77; P < 0.0001) and MDQ (R = 0.46, P = 0.001). After stratification by histological response, the LS decreased 70% in responders vs. 13% in non-responders (P = 0.02). In patients who did not receive baseline dilation, both the VAS and LS decreased significantly more in the histological responders.
Both the VAS and LS were responsive to successful treatment as measured by histologic improvement. Because the VAS and LS are simple to administer and are responsive to treatment, they can provide an efficient and objective method for assessing dysphagia severity in EoE in clinical practice.
虽然已开发出症状评分来评估嗜酸性粒细胞性食管炎(EoE)中的吞咽困难,但评分的复杂性可能会限制其临床应用。
评估视觉模拟量表(VAS)和10分制李克特量表(LS)在EoE治疗前后对吞咽困难严重程度的评估情况。
我们进行了一项前瞻性队列研究,纳入连续接受门诊内镜检查的成年人。根据共识指南诊断EoE的新发病例。在诊断时和治疗8周后,使用VAS、LS和梅奥吞咽困难问卷(MDQ)测量症状。比较治疗前后评分的总体变化百分比,以及治疗有反应者(嗜酸性粒细胞<15个/高倍视野)、无反应者和未进行基线扩张患者的评分变化百分比。
在51例EoE病例中,VAS中位数从基线时的3.6降至治疗后的1.4(下降71%),LS从6降至2(下降67%),MDQ从20降至10(下降49%)。VAS与LS(R = 0.77;P < 0.0001)和MDQ(R = 0.46,P = 0.001)均相关。按组织学反应分层后,有反应者的LS下降70%,无反应者下降13%(P = 0.02)。在未接受基线扩张的患者中,组织学有反应者的VAS和LS下降幅度均明显更大。
通过组织学改善衡量,VAS和LS对成功治疗均有反应。由于VAS和LS易于实施且对治疗有反应,它们可为临床实践中评估EoE吞咽困难严重程度提供一种有效且客观的方法。